On the stock market since 2022, it operates in the world of health and science. It has 69 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
The average analyst price target is $9.50 — 18% above today’s price.
A loss of $84.3M against $0 in annual sales.
This stock swings about 3.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
On our five-subject report card, VIGL sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VIGL is a high-risk stock — not yet profitable, and its future rides on its product catching on.